liver disease

A silver slightly shiny strands of DNA appear against a background of clocks
Biotech

NewLimit raises $130M to push liver mRNA med into clinic

NewLimit's first target is alcohol-related liver disease, but it hopes to use early indications as a stepping stone to broader patient groups.
Darren Incorvaia May 6, 2025 11:00am
Pencil filling out Scantron test form

AIRNA preps for clinical test with $155M series B

Apr 1, 2025 7:00am
arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Mar 26, 2025 10:00am
Ship sailing through stormy seas

Arbor sails into rocky gene editing waters with $74M

Mar 18, 2025 6:30am
u turn turnaround return

Vertex axes Verve gene editing pact amid shift in R&D priorities

Feb 27, 2025 9:05am
gold arrow pointing upward forward

Akero's stock doubles as midphase MASH trial hits the mark

Jan 27, 2025 8:31am